Incyte (NAS:INCY) Asset Turnover

: 0.15 (As of Sep. 2022)

View and export this data going back to 1993. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Incyte's Revenue for the three months ended in Sep. 2022 was $823 Mil. Incyte's Total Assets for the quarter that ended in Sep. 2022 was $5,415 Mil. Therefore, Incyte's Asset Turnover for the quarter that ended in Sep. 2022 was 0.15.

Asset Turnover is linked to ROE % through Du Pont Formula. Incyte's annualized ROE % for the quarter that ended in Sep. 2022 was 10.85%. It is also linked to ROA % through Du Pont Formula. Incyte's annualized ROA % for the quarter that ended in Sep. 2022 was 8.33%.

Incyte Asset Turnover Historical Data

The historical data trend for Incyte's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Asset Turnover

0.78

0.76

0.71

0.76

0.70

Incyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Asset Turnover																0.20	0.19	0.15	0.18	0.15

Competitive Comparison

For the Biotechnology subindustry, Incyte's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Incyte Asset Turnover Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Incyte's Asset Turnover falls in comparison to its industry or sector. The grey bar indicates the Asset Turnover's extreme value range as defined by GuruFocus.

Incyte Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Incyte's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (A: Dec. 2021 )	/	( (Total Assets (A: Dec. 2020 )	+	Total Assets (A: Dec. 2021 ))	/ count )
=	2986.267	/	( (3560.918	+	4933.352)	/ 2 )
=	2986.267	/	4247.135
=	0.70

Incyte's Asset Turnover for the quarter that ended in Sep. 2022 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (Q: Sep. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
=	823.303	/	( (5319.035	+	5510.214)	/ 2 )
=	823.303	/	5414.6245
=	0.15

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Incyte (NAS:INCY) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Incyte's annulized ROE % for the quarter that ended in Sep. 2022 is

	ROE %^**		(Q: Sep. 2022 )
=	Net Income	/	Total Stockholders Equity
=	451.1	/	4155.856
=	(Net Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(451.1 / 3293.212)	*	(3293.212 / 5414.6245)	*	(5414.6245/ 4155.856)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	13.7 %	*	0.6082	*	1.3029
=	ROA %	*	Equity Multiplier
=	8.33 %	*	1.3029
=	10.85 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.

^** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Incyte's annulized ROA % for the quarter that ended in Sep. 2022 is

	ROA %		(Q: Sep. 2022 )
=	Net Income	/	Total Assets
=	451.1	/	5414.6245
=	(Net Income / Revenue)	*	(Revenue / Total Assets)
=	(451.1 / 3293.212)	*	(3293.212 / 5414.6245)
=	Net Margin %	*	Asset Turnover
=	13.7 %	*	0.6082
=	8.33 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Incyte Asset Turnover Related Terms

Thank you for viewing the detailed overview of Incyte's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (NAS:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (NAS:INCY) » Definitions » Asset Turnover

Comparable Companies

Traded in Other Exchanges

INCY:Mexico 0J9P:UK ICY:Germany ICY:Germany I1NC34:Brazil INCY:Austria

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Executives

Tray Thomas	officer: Principal Accounting Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Brawley Otis W	director	5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518
High Katherine A	director	3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Harrigan Edmund	director
Morrissey Michael James	officer: EVP, Head of Tech. Operations	IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Dickinson Jonathan Elliott	officer: EVP, General Manager, Europe	CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Stamoulis Christiana	officer: EVP & Chief Financial Officer	C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139
Dhanak Dashyant	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Pasquale Maria E	officer: EVP & General Counsel	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Fouse Jacqualyn A	director	C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108
Iyengar Vijay K	officer: EVP GPS, BD, & Licensing	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Stein Steven H	officer: EVP & Chief Medical Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Trower Paul	officer: VP, Finance & Prin Acc Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Clancy Paul J	director	C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Bienaime Jean Jacques	director	925 PAGE MILL ROAD PALO ALTO CA 94304